Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$3.19 USD
-0.01 (-0.31%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $3.18 -0.01 (-0.31%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ALDX 3.19 -0.01(-0.31%)
Will ALDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?
Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra (ALDX) Stock Rallies 43% in One Week: Here's Why
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
Here's Why You Should Invest in Aldeyra (ALDX) Stock Now
Other News for ALDX
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
Aldeyra announces advancement of new RASP modulators, preclinical data
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aldeyra Therapeutics (ALDX), Cardinal Health (CAH) and Roche Holding AG (OtherRHHVF)
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for Reproxalap